Cargando…

The Rate of Cisplatin Dosing Affects the Resistance and Metastatic Potential of Triple Negative Breast Cancer Cells, Independent of Hypoxia

To best control tumor growth and/or metastasis in triple negative breast cancer (TNBC), it may be useful to understand the effect(s) of chemotherapy delivery (i.e., the rate and pattern of exposure to the drug) on cell sub-populations that have experienced different levels of hypoxia (and/or acidosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhatavdekar, Omkar, Godet, Inês, Gilkes, Daniele, Sofou, Stavroula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611288/ https://www.ncbi.nlm.nih.gov/pubmed/36297617 http://dx.doi.org/10.3390/pharmaceutics14102184

Ejemplares similares

Growth Inhibition of Triple-Negative Breast Cancer: The Role of Spatiotemporal Delivery of Neoadjuvant Doxorubicin and Cisplatin
por: Salerno, Dominick, et al.
Publicado: (2021)

Two diverse carriers are better than one: A case study in α‐particle therapy for prostate specific membrane antigen‐expressing prostate cancers
por: Salerno, Dominick, et al.
Publicado: (2021)

Detection of Hypoxia in Cancer Models: Significance, Challenges, and Advances
por: Godet, Inês, et al.
Publicado: (2022)

A software tool for the quantification of metastatic colony growth dynamics and size distributions in vitro and in vivo
por: Bhoyar, Soumitra, et al.
Publicado: (2018)

Post-Hypoxic Cells Promote Metastatic Recurrence after Chemotherapy Treatment in TNBC
por: Godet, Inês, et al.
Publicado: (2021)

Mebendazole Treatment Disrupts the Transcriptional Activity of Hypoxia-Inducible Factors 1 and 2 in Breast Cancer Cells
por: Joe, Natalie S., et al.
Publicado: (2023)

The rise of viperin: the emerging role of viperin in cancer progression
por: Weinstein, Alyssa G., et al.
Publicado: (2022)

Implications of Hypoxia in Breast Cancer Metastasis to Bone
por: Gilkes, Daniele M.
Publicado: (2016)

Radionuclide carriers for targeting of cancer
por: Sofou, Stavroula
Publicado: (2008)

Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer
por: Park, In Hae, et al.
Publicado: (2018)

Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
por: Wang, Junbin, et al.
Publicado: (2017)

Hypoxia-regulated carbonic anhydrase IX (CAIX) protein is an independent prognostic indicator in triple negative breast cancer
por: Ong, Chong Hui Clara, et al.
Publicado: (2022)

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
por: Li, Yi, et al.
Publicado: (2019)

Fate-mapping post-hypoxic tumor cells reveals a ROS-resistant phenotype that promotes metastasis
por: Godet, Inês, et al.
Publicado: (2019)

Differential Impact of EGFR-Targeted Therapies on Hypoxia Responses: Implications for Treatment Sensitivity in Triple-Negative Metastatic Breast Cancer
por: El Guerrab, Abderrahim, et al.
Publicado: (2011)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2014)

Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance
por: Hill, David P., et al.
Publicado: (2019)

A persistent invasive phenotype in post-hypoxic tumor cells is revealed by fate mapping and computational modeling
por: Rocha, Heber L., et al.
Publicado: (2021)

Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer
por: Anders, Carey K, et al.
Publicado: (2022)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
por: Nandini, Dey, et al.
Publicado: (2021)

Mebendazole prevents distant organ metastases in part by decreasing ITGβ4 expression and cancer stemness
por: Joe, Natalie S., et al.
Publicado: (2022)

miR-638 mediated regulation of BRCA1affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer
por: Tan, Xiaohui, et al.
Publicado: (2014)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2022)

Metastatic and triple-negative breast cancer: challenges and treatment options
por: Al-Mahmood, Sumayah, et al.
Publicado: (2018)

Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer
por: Saravia, César H, et al.
Publicado: (2019)

How I treat metastatic triple-negative breast cancer
por: Caparica, Rafael, et al.
Publicado: (2019)

Overview of recent advances in metastatic triple negative breast cancer
por: O'Reilly, David, et al.
Publicado: (2021)

Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer
por: Cipriano, Élia, et al.
Publicado: (2021)

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
por: Heeke, Arielle L., et al.
Publicado: (2021)

Emerging treatment strategies for metastatic triple-negative breast cancer
por: Huppert, Laura A., et al.
Publicado: (2022)

Hypoxia-mediated activation of hypoxia-inducible factor-1α in triple-negative breast cancer: A review
por: Liu, Lihui, et al.
Publicado: (2023)

Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens
por: Srivastava, Nityanand, et al.
Publicado: (2023)

Hypoxia-inducible factors enhance glutamate signaling in cancer cells
por: Hu, Hongxia, et al.
Publicado: (2014)

Hypoxia negatively affects senescence in osteoclasts and delays osteoclastogenesis
por: Gorissen, Ben, et al.
Publicado: (2018)

Cisplatin Loaded Multiwalled Carbon Nanotubes Induce Resistance in Triple Negative Breast Cancer Cells
por: Badea, Madalina Andreea, et al.
Publicado: (2018)

AKT isoforms have discrete expression in triple negative breast cancers and roles in cisplatin sensitivity
por: Wadhwa, Bhumika, et al.
Publicado: (2020)

Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
por: Kalra, Maitri, et al.
Publicado: (2021)

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells
por: Gajan, Ambikai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m4ir9up050unrt4784975tf8vg